Baricitinib for the Management of SARS-CoV-2-Infected Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

Figure 2

(a) The effect of baricitinib on mortality. (b) The effect of baricitinib on disease progression in COVID-19 patients. Marconi et al. [7] were contacted for additional information. The additional information was supplied by Eli Lilly, the sponsor company. The letter is supplied as supplementary file S2.

(a)

(b)